FDA Requiring Boxed Warning Update for Benzodiazepine Drug Class

1
438

From the U.S. Food & Drug Administration: “To address the serious risks of abuse, addiction, physical dependence, and withdrawal reactions, the U.S. Food and Drug Administration (FDA) is requiring the Boxed Warning be updated for all benzodiazepine medicines. Benzodiazepines are widely used to treat many conditions, including anxiety, insomnia, and seizures. The current prescribing information for benzodiazepines does not provide adequate warnings about these serious risks and harms associated with these medicines so they may be prescribed and used inappropriately. This increases these serious risks, especially when benzodiazepines are used with some other medicines and substances.”

Article →

Support MIA

MIA relies on the support of its readers to exist. Please consider a donation to help us provide news, essays, podcasts and continuing education courses that explore alternatives to the current paradigm of psychiatric care. Your tax-deductible donation will help build a community devoted to creating such change.

$
Select Payment Method
Personal Info

Credit Card Info
This is a secure SSL encrypted payment.

Billing Details

Donation Total: $20 One Time

1 COMMENT

  1. “Benzodiazepines are widely used to treat many conditions, including anxiety, insomnia, and seizures.”

    and the refusal of someone to give consent.

    “The current prescribing information for benzodiazepines does not provide adequate warnings about these serious risks and harms associated with these medicines so they may be prescribed and used inappropriately.”

    Problem being that they are being ‘prescribed’ by people with no prescribing rights to chemically restrain people and aid in the planting of evidence for police to find. The writing of a prescription by a real doctor 12 hours after they were administered seems to be a little late to check whether it is okay to be putting these intoxicating substances into peoples food or drink without their knowledge.

LEAVE A REPLY